会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 6. 发明授权
    • Heterocyclic amide derivatives as inhibitors of glycogen phosphorylase
    • 杂环酰胺衍生物作为糖原磷酸化酶的抑制剂
    • US07276517B2
    • 2007-10-02
    • US11463144
    • 2006-08-08
    • Alan Martin BirchAndrew David MorleyAndrew StockerPaul Robert Owen Whittamore
    • Alan Martin BirchAndrew David MorleyAndrew StockerPaul Robert Owen Whittamore
    • A61K31/4375C07D471/04
    • C07D495/04
    • Heterocyclic amides of formula (1) wherein: X is N or CH; R4 and R5 together are either —S—C(R6)═C(R7)— or —C(R7)═C(R6)—S—; R6 and R7 are independently selected from, for example hydrogen, halo and C1-4alkyl; A is phenylene or heteroarylene; n is 0, 1 or 2; R1 is selected from for example halo, nitro, cyano, hydroxy, carboxy; R2 is hydrogen, hydroxy or carboxy; R3 is selected from for example hydrogen, hydroxy, aryl, heterocyclyl and C1-4alkyl(optionally substituted by 1 or 2 R8 groups); R8 is selected from for example hydroxy, —COCOOR9, —C(O)N(R9)(R10), —NHC(O)R9, (R9)(R10)N— and —COOR9; R9 and R10 are selected from for example hydrogen, hydroxy, C1-4alkyl (optionally substituted by 1 or 2 R13); R13 is selected from hydroxy, halo, trihalomethyl and C1-4alkoxy; or a pharmaceutically acceptable salt or pro-drug thereof, possess glycogen phosphorylase inhibitory activity and accordingly have value in the treatment of disease states associated with increased glycogen phosphorylase activity. Processes for the manufacture of said heterocyclic amide derivatives and pharmaceutical compositions containing them are described.
    • 式(1)的杂环酰胺其中:X是N或CH; R 4和R 5一起是-SC(R 6)-C(R 7) - 或 -C(R 7)C(R 6)-S-; R 6和R 7独立地选自,例如氢,卤素和C 1-4烷基; A是亚苯基或亚杂芳基; n为0,1或2; R 1选自例如卤素,硝基,氰基,羟基,羧基; R 2是氢,羟基或羧基; R 3选自例如氢,羟基,芳基,杂环基和C 1-4烷基(任选被1或2个R 8取代) 组); R 8选自例如羟基,-COCOOR 9,-C(O)N(R 9)(R 10) ),-NHC(O)R 9,(R 9)(R 10)N - 和-COOR 9 ; R 9和R 10选自例如氢,羟基,C 1-4烷基(任选被1或2个R SUP取代 > 13 ); R 13选自羟基,卤素,三卤代甲基和C 1-4烷氧基; 或其药学上可接受的盐或前药具有糖原磷酸化酶抑制活性,因此在治疗与增加的糖原磷酸化酶活性相关的疾病状态方面具有价值。 描述了制备所述杂环酰胺衍生物和含有它们的药物组合物的方法。